九安医疗(002432) - 2025 Q2 - 季度业绩预告

Projected Performance for the Current Period The company anticipates a year-on-year increase in its 2025 first-half performance, with net profit attributable to shareholders projected to be between 880 million and 980 million yuan, representing a 46.24% to 62.86% growth, and net profit after deducting non-recurring gains and losses expected to range from 860 million to 960 million yuan, a 23.29% to 37.63% increase Performance Forecast Summary | Item | Current Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Profit: 880 million - 980 million yuan | Profit: 601.76 million yuan | | Year-on-Year Growth | 46.24% - 62.86% | - | | Net Profit After Deducting Non-Recurring Gains and Losses | Profit: 860 million - 960 million yuan | Profit: 697.55 million yuan | | Year-on-Year Growth | 23.29% - 37.63% | - | | Basic Earnings Per Share | Profit: 2.0129 - 2.2416 yuan/share | Profit: 1.3788 yuan/share | Communication Status with Accounting Firm The company explicitly states that the performance forecast data released herein has not been audited by an accounting firm - This performance forecast has not been audited by an accounting firm[4] Explanation of Performance Changes The significant increase in net profit for the current period is primarily driven by the strong performance of the company's asset management business, with investment income and fair value changes recognized as recurring gains and losses, alongside stable consumer demand for regular medical products like test kits, and expanded market presence through online and offline channels including Amazon, CVS, and Walmart, with plans to leverage the iHealth brand for continuous new product launches - Performance growth is primarily attributed to the strong performance of the asset management business's asset allocation, with investment income and fair value changes recognized as recurring gains and losses[5] - The company's test kit products, as regular household consumer goods, maintain sustained market demand and have achieved extensive coverage across major online and offline retail channels including Amazon, CVS, and Walmart[5][6] - The company will leverage its iHealth brand advantage to continuously expand its home medical and health electronics product line, introducing competitive new products to the international market[6] Risk Warning The company advises investors that the financial data in this announcement represents preliminary calculations by the finance department and has not been audited, thus the final data may differ from the official figures disclosed in the 2025 semi-annual report, urging investors to be aware of investment risks - The financial data in this announcement is preliminary and unaudited, and may differ from the final data disclosed in the semi-annual report[7] Other Explanatory Matters The company's designated information disclosure media are Securities Times and Juchao Information Network (www.cninfo.com.cn) - The company's designated information disclosure media are Securities Times and Juchao Information Network[8]